Pathogenic variants in 23 genes with a higher contribution of other susceptibility cancer genes (54%) than BRCA1/2 (46%). High frequency of Mexican founder mutations (e.g. del exons 9-12, p.G228fs in BRCA1). This evidence concerns the gene BRCA1 and cancer.